This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abe, A., J. Inokuchi, et al. (1992). “Improved inhibitors of glucosylceramide synthase.” J Biochem Tokyo 111(2): 191–6.
Aerts, J. M. and C. E. Hollak (1997). “Plasma and metabolic abnormalities in Gaucher’s disease.” Baillieres Clin Haematol 10(4): 691–709.
Andersson, U., T. D. Butters, et al. (2000). “N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.” Biochem Pharmacol 59(7): 821–9.
Andersson, U., D. Smith, et al. (2004). “Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.” Neurobiol Dis 16(3): 506–15.
Bektas, M. and S. Spiegel (2004). “Glycosphingolipids and cell death.” Glycoconj J 20(1): 39–47.
Beutler, E. and G. Grabowski (2001). Gaucher disease. The metabolic and molecular bases of inherited diseases. C. R. Scriver, A. L. Beadet, D. Valle and W. S. Sly. New York, McGraw Hill. 3: 3636–3668.
Brady, R. O. (2003). “Enzyme replacement therapy: conception, chaos and culmination.” Philos Trans R Soc Lond B Biol Sci 358(1433): 915–9.
Butters, T. D., R. A. Dwek, et al. (2003). “Therapeutic applications of imino sugars in lysosomal storage disorders.” Curr Top Med Chem 3(5): 561–74.
Butters, T. D., H. R. Mellor, et al. (2003). “Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.” Philos Trans R Soc Lond B Biol Sci 358(1433): 927–45.
Butters, T. D., L. A. G. M. van den Broek, et al. (2000). “Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycospingolipid biosynthesis.” Tetrahedron Assymetry 11: 113–124.
Cabrera-Salazar, M. A., E. Novelli, et al. (2002). “Gene therapy for the lysosomal storage disorders.” Curr Opin Mol Ther 4(4): 349–58.
Chujor, C. S. N., K. R. Feingold, et al. (1998). “Glucosylceramide synthase activity in murine epidermis: quantitation, localization, regulation, and requirement for barrier homeostasis.” J Lipid Res 39(2):277–285.
Cox, T., R. Lachmann, et al. (2000). “Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.” Lancet 355(9214): 1481–5.
Cox, T. M., J. M. Aerts, et al. (2003). “The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.” J Inherit Metab Dis 26(6): 513–26.
Dobrenis, K. (2004). Cell-mediated delivery systems. Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley. Oxford, Oxford University Press: 339–380.
Elstein, D., C. Hollak, et al. (2004). “Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT-918) in type 1 Gaucher disease.” J Inherit Metab Dis In Press.
Erikson, A., C. G. Groth, et al. (1990). “Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type.” Acta-Paediatr-Scand 79(6–7): 680–5.
Futerman, A. H. and R. E. Pagano (1991). “Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver.” Biochem J 280(Pt 2): 295–302.
Galbiati, F., B. Razani, et al. (2001). “Emerging themes in lipid rafts and caveolae.” Cell 106(4): 403–11.
Ginzburg, L., Y. Kacher, et al. (2004). “The pathogenesis of glycosphingolipid storage disorders.” Semin Cell Dev Biol 15(4): 417–31.
Ichikawa, S. and Y. Hirabayashi (1998). “Glucosylceramide synthase and glycosphingolipid synthesis.” Tr Cell Biol 8(5): 198–202.
Ichikawa, S., N. Nakajo, et al. (1994). “A mouse B16 melanoma mutant deficient in glycolipids.” Proc Natl Acad Sci U S A 91(7): 2703–7.
Ichikawa, S., K. Ozawa, et al. (1998). “Molecular cloning and characterization of the mouse ceramide glucosyltransferase gene.” Biochem Biophys Res Commun 253(3): 707–11.
Ichikawa, S., H. Sakiyama, et al. (1996). “Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis.” Proc Natl Acad Sci USA 93(10): 4638–43.
Inokuchi, J. and N. S. Radin (1987). “Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase.” J Lipid Res 28(5): 565–71.
Jeyakumar, M., T. D. Butters, et al. (1999). “Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.” Proc. Natl.Acad. Sci. U.S.A. 96(11):6388–6393.
Jeyakumar, M., T. D. Butters, et al. (2002). “Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.” Neuropathol Appl Neurobiol 28(5): 343–57.
Jeyakumar, M., D. Smith, et al. (2004). “NSAIDS incraese survival in the Sandhoff disease mouse: synergy with NB-DNJ.” Annals of Neurology In Press.
Jeyakumar, M., R. Thomas, et al. (2003). “Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.” Brain 126(Pt 4): 974–87.
Kobayashi, T. and Y. Hirabayashi (2000). “Lipid membrane domains in cell surface and vacuolar systems.” Glycoconj J 17(3–4): 163–71.
Krivit, W., J. H. Sung, et al. (1995). “Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases.” Cell-Transplant 4(4): 385–92.
Lachmann, R. H. (2003). “Miglustat. Oxford GlycoSciences/Actelion.” Curr Opin Investig Drugs 4(4):472–9.
Lachmann, R. H. and F. M. Platt (2001). “Substrate reduction therapy for glycosphingolipid storage disorders.” Exp. Opin. Invest. Drugs 10: 455–466.
Maccioni, H. J., J. L. Daniotti, et al. (1999). “Organization of ganglioside synthesis in the Golgi apparatus.” Biochim Biophys Acta 1437(2): 101–18.
Meikle, P. J., J. J. Hopwood, et al. (1999). “Prevalence of lysosomal storage disorders.” JAMA 281(3): 249–54.
Moyses, C. (2003). “Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.” Philos Trans R Soc Lond B Biol Sci 358(1433): 955–60.
Munro, S. (2003). “Lipid rafts: elusive or illusive?” Cell 115(4): 377–88.
Neufeld, E. F. (2004). Enzyme replacement therapy. Lysosomal disorders of the brain. F. M. Platt and S. U. Walkley. Oxford, Oxford University Press: 327–338.
Pagano, R. E., V. Puri, et al. (2000). “Membrane traffic in sphingolipid storage diseases.” Traffic 1(11): 807–15.
Platt, F. M. and T. D. Butters (2004). Inhibition of substrate synthesis: a pharmacological approach for glycosphingolipid storage disease therapy. Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley. Oxford, Oxford University Press: 381–408.
Platt, F. M., G. R. Neises, et al. (1994a). “N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.” J Biol Chem 269(11): 8362–5.
Platt, F. M., G. R. Neises, et al. (1994b). “N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.” J Biol Chem 269(43): 27108–14.
Platt, F. M. and S. U. Walkley (2004). Lysosomal defects and storage. Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley. Oxford, Oxford University Press: 32–49.
Radin, N. S. (1996). “Treatment of Gaucher disease with an enzyme inhibitor.” Glycoconj J 13(2): 153–7.
Ringden, O., C. G. Groth, et al. (1995). “Ten years’ experience of bone marrow transplantation for Gaucher disease.” Transplantation 59(6): 864–70.
Sandhoff, K. and T. Kolter (2003). “Biosynthesis and degradation of mammalian glycosphingolipids.” Philos Trans R Soc Lond B Biol Sci 358(1433): 847–61.
Sango, K., S. Yamanaka, et al. (1995). “Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.” Nat Genet 11(2): 170–6.
Schiffmann, R. and R. O. Brady (2002). “New prospects for the treatment of lysosomal storage diseases.” Drugs 62(5): 733–42.
Simpson, M. A., H. Cross, et al. (2004). “Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.” Nature Genetics In Press.
Snyder, E. Y., G. Q. Daley, et al. (2004). “Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system.” J Neurosci Res 76(2): 157–68.
Trinchera, M., M. Fabbri, et al. (1991). “Topography of glycosyltransferases involved in the initial glycosylations of gangliosides.” J-Biol-Chem 266(31): 20907–12 issn: 0021-9258.
Wada, R., C. J. Tifft, et al. (2000). “Microglial activation precedes acute neurodegeneration in Sandhoff disease and is supressed by bone marrow transplantation.” Proc Natl Acad Sci USA 97(20):10954–10959.
Walkley, S. U. (2004). “Secondary accumulation of gangliosides in lysosomal storage disorders.” Semin Cell Dev Biol 15(4): 433–44.
Walkley, S. U., M. Zervas, et al. (2000). “Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons.” Cereb Cortex 10(10): 1028–37.
Warnock, D. E., M. S. Lutz, et al. (1994). “Transport of newly synthesized glucosylceramide to the plasma membrane by a non-Golgi pathway.” Proc Natl Acad Sci U S A 91(7): 2708–12.
Winchester, B. (2004). Primary defects in lysosomal enzymes. Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley, Oxford University Press: 81–130.
Winchester, B. and G. W. Fleet (1992). “Amino-sugar glycosidase inhibitors: versatile tools for glycobiologists.” Glycobiology 2(3): 199–210.
Wraith, J. E. (2004). Clinical aspects and diagnosis. Lysosomal disorders of the brain. F. M. Platt and S. U. Walkley. Oxford, Oxford University Press: 50–77.
Wu, Y. P. and R. L. Proia (2004). “Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.” Proc Natl Acad Sci U S A 101(22): 8425–30.
Yamashita, T., R. Wada, et al. (1999). “A vital role for glycosphingolipid synthesis during development and differentiation.” Proc. Natl. Acad. Sci. USA 96: 9142–9147.
Zervas, M., K. L. Somers, et al. (2001). “Critical role for glycosphingolipids in Niemann-Pick disease type C.” Curr Biol 11(16): 1283–7.
Zhang, X. and F. L. Kiechle (2004). “Review: Glycosphingolipids in health and disease.” Ann Clin Lab Sci 34(1): 3–13.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this paper
Cite this paper
Platt, F.M., Jeyakumar, M., Andersson, U., Dwek, R.A., Butters, T.D. (2005). New Developments in Treating Glycosphingolipid Storage Diseases. In: Axford, J.S. (eds) Glycobiology and Medicine. Advances in Experimental Medicine and Biology. Springer, Boston, MA. https://doi.org/10.1007/0-387-25515-X_21
Download citation
DOI: https://doi.org/10.1007/0-387-25515-X_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25514-9
Online ISBN: 978-0-387-25515-6
eBook Packages: MedicineMedicine (R0)